Real Efficacy is long-standing
Proven protection during 20 years of clinical experience*
Documented efficacy in previously treated patients1
In clinical trials with PTPs, 93.5% of bleeds rated as mild, moderate, and severe were treated with 1 or 2 infusions, 80% with just 1 infusion.1
*With the Kogenate® product line.
Long history of published evidence
Documented efficacy in previously untreated/minimally treated patients2
In clinical trials with PUPs and MTPs, 89.2% of all episodes were treated with 1 or 2 infusions, and 74.0% were treated with just 1 infusion.2
References:
- Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy—International Kogenate-FS Study Group. Thromb Haemost. 2000; 83(6):811-816.
- Kreuz W, Gill JC, Rothschild C, et al; International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005; 9(3):457-467.
